Teva Expands Management Team with Appointment of Dr. Ivana Magovčević-Liebisch as Senior Vice President, Head of Corporate Business Development​

Teva Expands Management Team with Appointment of Dr. Ivana Magovčević-Liebisch as Senior Vice President, Head of Corporate Business Development​

Jerusalem, Mar. 18, 2013 -- Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) today announced that Ivana Magovčević-Liebisch, Ph.D., J.D., has been appointed Senior Vice President, Head of Corporate Business Development.  Dr. Magovčević-Liebisch's appointment is effective April 1, 2013.

"Teva continues to build its premier leadership team, and we anticipate that Ivana, with her track record in partnering and licensing agreements and her extensive industry experience from R&D to Commercial Operations, will play an important role in the ongoing success of our business development programs," stated Ika Abravanel, Teva's Group Executive Vice President, Human Resources & Chief Integration Officer.  "At Teva, we are recruiting the best talent and are committed to a disciplined approach to transactions."

About Dr. Magovčević-Liebisch

Prior to joining Teva, Dr. Magovčević-Liebisch held several senior management positions at Dyax Corp., attaining the role of Executive Vice President and Chief Operating Officer.  In this position, she oversaw commercial operations and managed business development and alliance management, as well as legal affairs, information technology and research.  Previously, she was Director of Intellectual Property and Patent Counsel for Transkaryotic Therapies, Inc.  Dr. Magovčević-Liebisch received her Ph.D. degree in genetics from Harvard University and her law degree from Suffolk University Law School in Boston.

About Teva

Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) is a leading global pharmaceutical company, committed to increasing access to high-quality healthcare by developing, producing and marketing affordable generic drugs as well as innovative and specialty pharmaceuticals and active pharmaceutical ingredients.  Headquartered in Israel, Teva is the world's leading generic drug maker, with a global product portfolio of more than 1,000 molecules and a direct presence in about 60 countries.  Teva's branded businesses focus on CNS, oncology, pain, respiratory and women's health therapeutic areas as well as biologics.  Teva currently employs approximately 46,000 people around the world and reached $20.3 billion in net revenues in 2012.

 

Suggested Articles

J&J's talc woes deepened Friday after the FDA turned up "sub-trace" levels of asbestos one bottle of the company's baby powder,…

Another major drugmaker is recalling in the U.K. 10 batches of its Zantac generics because they contain a possible carcinogen.

With diagnosis rates on the rise, Pfizer's Vyndaqel franchise could collect $157 million in 2019 U.S. sales, well above consensus, SVB Leerink says.